FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980147894> ?p ?o ?g. }

• W2980147894 endingPage "79" @default.
• W2980147894 startingPage "74" @default.
• W2980147894 abstract "Sebaceous carcinoma of the ocular and periocular regions showed expression of immune checkpoint ligands PD-1, PD-L1, and PD-L2, which suggests PD blockade may provide benefit as an adjuvant therapy for patients with sebaceous carcinoma. Purpose: Sebaceous carcinoma can be highly malignant and difficult to treat. Surgical excision followed by periocular reconstruction is the primary method of treatment. In aggressive cases, radiation, topical chemotherapy, and systemic chemotherapy have been explored as adjuvant therapy. Immunotherapy, through immune checkpoint inhibitors, has proven to have significant antitumor effect in many cancer types, including melanoma, non-small cell lung cancer, renal cell carcinoma, and cutaneous squamous cell carcinoma. Little is known about endogenous immune response directed against sebaceous carcinoma. In this study, we aim to characterize the expression pattern of PD-1 and its ligands PD-L1 and PD-L2 in both sebaceous carcinoma and in infiltrating immune cells to explore the potential use of checkpoint blockade as therapy. Methods: We performed a retrospective chart and histology review of patients with sebaceous carcinoma between 1990 and 2017 at the University of Wisconsin. Tissue microarrays were made from paraffin blocks. Immunohistochemistry was performed for evaluation of tumor and immune cell infiltration for expression of PD-1, PD-L1, and PD-L2. Tumor or infiltrating immune cells were considered positive if ≥5% of cells had membranous (cell surface) expression. Results: Twenty-eight patients were included. PD-L1 and PD-1 were not significantly expressed on tumor cells; however, PD-L1 and PD-1 were expressed on infiltrating immune cells in 46% and 25% of patients, respectively. In contrast, PD-L2 demonstrated positive expression on tumor cells in 46% of the cases along with positive expression on infiltrating immune cells in 38% of the cases. Conclusions: Sebaceous carcinoma currently has few effective adjuvant treatment options. The expression of PD-1, PD-L1, and PD-L2 on infiltrating immune cells and PD-L2 on tumor cells restrains T-cells from full activation and proliferation, therefore limiting the antitumor effect of T-cells, tipping the balance toward unopposed tumor progression. Consequently, PD-1 or PD-L1 inhibitors may have a role in sebaceous carcinoma treatment. Given the prevalence of PD-L2 expression in sebaceous carcinoma and the lack of PD-L2 blockade therapy available, PD-1 blockade may provide benefit over PD-L1 inhibitors. PD-1 blockade in combination with current methods may be a viable therapeutic option for patients with sebaceous carcinoma and deserves further study." @default.
• W2980147894 created "2019-10-18" @default.
• W2980147894 creator A5034385286 @default.
• W2980147894 creator A5064525410 @default.
• W2980147894 creator A5072103681 @default.
• W2980147894 creator A5083929048 @default.
• W2980147894 creator A5087737015 @default.
• W2980147894 date "2020-01-01" @default.
• W2980147894 modified "2023-10-17" @default.
• W2980147894 title "The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma" @default.
• W2980147894 cites W1486475418 @default.
• W2980147894 cites W1561024343 @default.
• W2980147894 cites W1786251417 @default.
• W2980147894 cites W2016983859 @default.
• W2980147894 cites W2020573722 @default.
• W2980147894 cites W2036958461 @default.
• W2980147894 cites W2039270548 @default.
• W2980147894 cites W2042300267 @default.
• W2980147894 cites W2057893793 @default.
• W2980147894 cites W2071865120 @default.
• W2980147894 cites W2075819066 @default.
• W2980147894 cites W2085645790 @default.
• W2980147894 cites W2104347254 @default.
• W2980147894 cites W2107752337 @default.
• W2980147894 cites W2109485845 @default.
• W2980147894 cites W2120891390 @default.
• W2980147894 cites W2124427232 @default.
• W2980147894 cites W2143772132 @default.
• W2980147894 cites W2160834915 @default.
• W2980147894 cites W2171600804 @default.
• W2980147894 cites W2313521660 @default.
• W2980147894 cites W2323153052 @default.
• W2980147894 cites W2339890238 @default.
• W2980147894 cites W2431949017 @default.
• W2980147894 cites W2467885539 @default.
• W2980147894 cites W2528906170 @default.
• W2980147894 cites W2603440175 @default.
• W2980147894 cites W2733272327 @default.
• W2980147894 cites W2767748351 @default.
• W2980147894 cites W2805968856 @default.
• W2980147894 cites W2806358063 @default.
• W2980147894 cites W2884610513 @default.
• W2980147894 cites W2888338846 @default.
• W2980147894 cites W2899789746 @default.
• W2980147894 cites W2900650889 @default.
• W2980147894 cites W2917133897 @default.
• W2980147894 cites W2933724412 @default.
• W2980147894 doi "https://doi.org/10.1097/iop.0000000000001472" @default.
• W2980147894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31593039" @default.
• W2980147894 hasPublicationYear "2020" @default.
• W2980147894 type Work @default.
• W2980147894 sameAs 2980147894 @default.
• W2980147894 citedByCount "7" @default.
• W2980147894 countsByYear W29801478942020 @default.
• W2980147894 countsByYear W29801478942021 @default.
• W2980147894 countsByYear W29801478942022 @default.
• W2980147894 crossrefType "journal-article" @default.
• W2980147894 hasAuthorship W2980147894A5034385286 @default.
• W2980147894 hasAuthorship W2980147894A5064525410 @default.
• W2980147894 hasAuthorship W2980147894A5072103681 @default.
• W2980147894 hasAuthorship W2980147894A5083929048 @default.
• W2980147894 hasAuthorship W2980147894A5087737015 @default.
• W2980147894 hasConcept C126322002 @default.
• W2980147894 hasConcept C142724271 @default.
• W2980147894 hasConcept C143998085 @default.
• W2980147894 hasConcept C193270364 @default.
• W2980147894 hasConcept C203014093 @default.
• W2980147894 hasConcept C204232928 @default.
• W2980147894 hasConcept C2776694085 @default.
• W2980147894 hasConcept C2776835612 @default.
• W2980147894 hasConcept C2777546739 @default.
• W2980147894 hasConcept C2777701055 @default.
• W2980147894 hasConcept C2777982462 @default.
• W2980147894 hasConcept C2780851360 @default.
• W2980147894 hasConcept C502942594 @default.
• W2980147894 hasConcept C71924100 @default.
• W2980147894 hasConcept C8891405 @default.
• W2980147894 hasConceptScore W2980147894C126322002 @default.
• W2980147894 hasConceptScore W2980147894C142724271 @default.
• W2980147894 hasConceptScore W2980147894C143998085 @default.
• W2980147894 hasConceptScore W2980147894C193270364 @default.
• W2980147894 hasConceptScore W2980147894C203014093 @default.
• W2980147894 hasConceptScore W2980147894C204232928 @default.
• W2980147894 hasConceptScore W2980147894C2776694085 @default.
• W2980147894 hasConceptScore W2980147894C2776835612 @default.
• W2980147894 hasConceptScore W2980147894C2777546739 @default.
• W2980147894 hasConceptScore W2980147894C2777701055 @default.
• W2980147894 hasConceptScore W2980147894C2777982462 @default.
• W2980147894 hasConceptScore W2980147894C2780851360 @default.
• W2980147894 hasConceptScore W2980147894C502942594 @default.
• W2980147894 hasConceptScore W2980147894C71924100 @default.
• W2980147894 hasConceptScore W2980147894C8891405 @default.
• W2980147894 hasIssue "1" @default.
• W2980147894 hasLocation W29801478941 @default.
• W2980147894 hasOpenAccess W2980147894 @default.
• W2980147894 hasPrimaryLocation W29801478941 @default.
• W2980147894 hasRelatedWork W129420824 @default.
• W2980147894 hasRelatedWork W1470985608 @default.

• next